Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.

Trial Profile

Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 15 Nov 2017 Planned End Date changed from 23 Aug 2018 to 24 Sep 2018.
    • 15 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Aug 2017 Planned End Date changed from 6 Jun 2018 to 23 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top